At a glance
- Capromorelin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 42 publications mentioning it, including 4 randomized controlled trials and 26 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates.
- The Effect of Capromorelin and Extended-Release Buprenorphine on Body Weight in Guinea Pigs (Cavia porcellus).
- Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial.
- Assessment of clinically relevant drugs as feline P-glycoprotein substrates.
- Clinical therapeutics in feline medicine: updates for old and new drugs.
- Effects of Capromorelin, Mirtazapine, and Cyproheptadine on Food Intake in Budgerigars (Melopsittacus undulatus).
- The 4 prokinetic drugs metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy New Zealand rabbits (Oryctolagus cuniculus).
- Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency.
- Effect of Capromorelin on Appetite and Weight Gain of Domestic Pigeons (Columba livia domestica).
- Investigating the Effect of Enterally Administered Capromorelin on Body Weight in Mice (Mus musculus).
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.